Literature DB >> 23880940

Par6 is phosphorylated by aPKC to facilitate EMT.

Adrian Gunaratne1, Gianni M Di Guglielmo.   

Abstract

The conserved polarity proteins Par6 and aPKC regulate cell polarization processes. However, increasing evidence also suggests that they play a role in oncogenic progression. During tumor progression, epithelial to mesenchymal transition (EMT) delineates an evolutionary conserved process that converts stationary epithelial cells into mesenchymal cells, which have an acquired ability for independent migration and invasion. In addition to signaling pathways that alter genetic programes that trigger the loss of cell-cell adhesion, alternative pathways can alter cell plasticity to regulate cell-cell cohesion and increase invasive potential. One such pathway involves TGFβ-induced phosphorylation of Par6. In epithelial cells, Par6 phosphorylation results in the dissolution of junctional complexes, cytoskeletal remodelling, and increased metastatic potential. Recently, we found that aPKC can also phosphorylate Par6 to drive EMT and increase the migratory potential of non-small cell lung cancer cells. This result has implications with respect to homeostatic and developmental processes involving polarization, and also with respect to cancer progression-particularly since aPKC has been reported to be an oncogenic regulator in various tumor cells.

Entities:  

Keywords:  EMT; Par3; Par6; RhoA; Smurf1; TGFβ; aPKC; cell polarity

Mesh:

Substances:

Year:  2013        PMID: 23880940      PMCID: PMC3739812          DOI: 10.4161/cam.25651

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  60 in total

1.  Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; John A Copland; E Aubrey Thompson; Alan P Fields
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

2.  Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control.

Authors:  Victoria Aranda; Teresa Haire; Marissa E Nolan; Joseph P Calarco; Avi Z Rosenberg; James P Fawcett; Tony Pawson; Senthil K Muthuswamy
Journal:  Nat Cell Biol       Date:  2006-10-22       Impact factor: 28.824

Review 3.  Regulation of Par6 by extracellular signals.

Authors:  Rohit Bose; Jeffrey L Wrana
Journal:  Curr Opin Cell Biol       Date:  2006-02-20       Impact factor: 8.382

4.  Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; Andras Khoor; Eric S Edell; Christine M Lohse; Alan P Fields
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

5.  Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.

Authors:  Ezra Eddy Wyssam Cohen; Mark W Lingen; Bangmin Zhu; Hongyan Zhu; Michael Wayne Straza; Carolyn Pierce; Leslie E Martin; Marsha Rich Rosner
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Ciota-mediated attenuation of p38 MAP kinase signaling.

Authors:  R M Baldwin; M Garratt-Lalonde; D A E Parolin; P M Krzyzanowski; M A Andrade; I A J Lorimer
Journal:  Oncogene       Date:  2006-05-11       Impact factor: 9.867

7.  Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer.

Authors:  Carl C Schimanski; Gösta Schmitz; Anuba Kashyap; Anja K Bosserhoff; Frauke Bataille; Stephan C Schäfer; Hans A Lehr; Martin R Berger; Peter R Galle; Susanne Strand; Dennis Strand
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

8.  A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.

Authors:  Melody Stallings-Mann; Lee Jamieson; Roderick P Regala; Capella Weems; Nicole R Murray; Alan P Fields
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

9.  Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.

Authors:  Eda Erdogan; Trond Lamark; Melody Stallings-Mann; Maurizio Pellecchia; Mauricio Pellechia; E Aubrey Thompson; Terje Johansen; Alan P Fields
Journal:  J Biol Chem       Date:  2006-07-22       Impact factor: 5.157

10.  Cdc42 and Par6-PKCzeta regulate the spatially localized association of Dlg1 and APC to control cell polarization.

Authors:  Sandrine Etienne-Manneville; Jean-Baptiste Manneville; Sarah Nicholls; Michael A Ferenczi; Alan Hall
Journal:  J Cell Biol       Date:  2005-09-12       Impact factor: 10.539

View more
  11 in total

Review 1.  PAR3-PAR6-atypical PKC polarity complex proteins in neuronal polarization.

Authors:  Sophie M Hapak; Carla V Rothlin; Sourav Ghosh
Journal:  Cell Mol Life Sci       Date:  2018-04-25       Impact factor: 9.261

Review 2.  Apico-basal polarity complex and cancer.

Authors:  Mohammed Khursheed; Murali Dharan Bashyam
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

3.  Deletion of Lats1/2 in adult kidney epithelia leads to renal cell carcinoma.

Authors:  Phoebe Carter; Ulrike Schnell; Christopher Chaney; Betty Tong; Xinchao Pan; Jianhua Ye; Glenda Mernaugh; Jennifer L Cotton; Vitaly Margulis; Junhao Mao; Roy Zent; Bret M Evers; Payal Kapur; Thomas J Carroll
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

Review 4.  Cell polarity signaling in the plasticity of cancer cell invasiveness.

Authors:  Aneta Gandalovičová; Tomáš Vomastek; Daniel Rosel; Jan Brábek
Journal:  Oncotarget       Date:  2016-05-03

5.  Suppression of CIP4/Par6 attenuates TGF-β1-induced epithelial-mesenchymal transition in NRK-52E cells.

Authors:  Ying-Chun Zhu; Ya-Kun Wang; Shou-Jun Bai; Fang-Fang Zha; Gang Feng; Cong-Pu Gao; Juan Liu
Journal:  Int J Mol Med       Date:  2017-08-16       Impact factor: 4.101

6.  Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis.

Authors:  Wishrawana S Ratnayake; André H Apostolatos; David A Ostrov; Mildred Acevedo-Duncan
Journal:  Int J Oncol       Date:  2017-09-22       Impact factor: 5.650

7.  Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors.

Authors:  Wishrawana S Ratnayake; Christopher A Apostolatos; André H Apostolatos; Ryan J Schutte; Monica A Huynh; David A Ostrov; Mildred Acevedo-Duncan
Journal:  Cell Adh Migr       Date:  2018-05-21       Impact factor: 3.405

8.  Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion.

Authors:  Wishrawana S Ratnayake; Christopher A Apostolatos; Sloan Breedy; Clare L Dennison; Robert Hill; Mildred Acevedo-Duncan
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

9.  A novel non‑selective atypical PKC agonist could protect neuronal cell line from Aβ‑oligomer induced toxicity by suppressing Aβ generation.

Authors:  Dongmei Zou; Qian Li; Wenyang Pan; Peng Chen; Miao Sun; Xiaofeng Bao
Journal:  Mol Med Rep       Date:  2022-03-04       Impact factor: 2.952

Review 10.  The Regulation of NFE2L2 (NRF2) Signalling and Epithelial-to-Mesenchymal Transition in Age-Related Macular Degeneration Pathology.

Authors:  Juha M T Hyttinen; Ram Kannan; Szabolcs Felszeghy; Minna Niittykoski; Antero Salminen; Kai Kaarniranta
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.